Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study

Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study

Abstract Background Prostate cancer (PCa) patients receiving radiotherapy may be predisposed to secondary malignancies. This study aimed to determine the association between PCa treatments, including radical prostatectomy (RP), external beam radiation therapy (EBRT), brachytherapy (BT) and androgen...

Full description

Bibliographic Details
Main Authors:	Patricia Grisel Quintana Bárcena, Armen Garo Aprikian, Alice Dragomir
Format:	Article
Language:	English
Published:	Wiley 2024-02-01
Series:	Cancer Medicine
Subjects:	androgen deprivation therapy bladder cancer brachytherapy colorectal cancer external beam radiation therapy prostate cancer
Online Access:	https://doi.org/10.1002/cam4.6922

Similar Items

Irradiation of localized prostate cancer in the elderly: A systematic literature review
by: Delphine Marotte, et al.
Published: (2022-07-01)

Cell‐by‐cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression
by: Seta Derderian, et al.
Published: (2023-07-01)

Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities
by: A. Gomez-Iturriaga, et al.
Published: (2024-03-01)

Incidence of prostate cancer in transgender women undergoing androgen deprivation therapy: A review
by: Saurabh Tyagi, et al.
Published: (2023-01-01)

Iodine-125 brachytherapy and robotic stereotactic radiotherapy — treatment options for patients with localized prostate cancer
by: E. A. Kiprijanov, et al.
Published: (2021-12-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

Cancer Therapy–Related Cardiac Dysfunction in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
by: Dong‐Yi Chen, et al.
Published: (2023-10-01)

Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections
by: Sooraj Kakkat, et al.
Published: (2023-04-01)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
by: Maree Pechlivanis, et al.
Published: (2021-12-01)

Triple combination therapy for clinically nonmetastatic super‐high‐risk prostate cancer
by: Koji Yoshimura, et al.
Published: (2022-07-01)

Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
by: Yutaka Yamamoto, et al.
Published: (2024-03-01)

Recent Advances in Advance Prostate Cancer
by: Nishant Lohia
Published: (2022-12-01)

Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study
by: Vaios-Konstantinos Mytilekas, et al.
Published: (2023-11-01)

Hormonal Therapies for Patients with Advanced Prostate Cancer
by: Cora N. Sternberg, et al.
Published: (2016-01-01)

Cardiometabolic and Skeletal Risk Factors in Black Men with Prostate Cancer Starting Androgen Deprivation Therapy
by: Orvar Gunnarsson, et al.
Published: (2015-04-01)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
by: Yue Wang, et al.
Published: (2017-01-01)

Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2021-03-01)

Exercise Adherence in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis
by: Kellie Toohey, et al.
Published: (2022-05-01)

Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer
by: Tore Bach-Gansmo, et al.
Published: (2022-06-01)

Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
by: Bassel Nazha, et al.
Published: (2022-06-01)

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
by: Norman J. Maitland
Published: (2021-01-01)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
by: Maryam Labaf, et al.
Published: (2022-11-01)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Iván Henríquez, et al.
Published: (2021-09-01)

Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
by: Hisham F. Bahmad, et al.
Published: (2022-02-01)

Prostate Cancer, Treatment and Response of the Hematological System in Mexican Population
by: Shaila Cejudo-Arteaga, et al.
Published: (2023-07-01)

Analysis of factors related to osteoporotic vertebral fracture in prostate cancer patients
by: Shunfa Huang, et al.
Published: (2024-02-01)

Should We Reconsider the Necessity of a Refinement of Prostate Cancer Risk Classification and Radiotherapy Treatment Strategy? Experiences from a Retrospective Analysis of Data from a Single Institution
by: Viktória Temesfői, et al.
Published: (2020-12-01)

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT
by: Zeina Ayoub, et al.
Published: (2022-12-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone
by: Francesco A. Mistretta, et al.
Published: (2022-05-01)

Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer
by: Nitya V. Sharma, et al.
Published: (2018-10-01)

AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
by: Mads Dochedahl Winther, et al.
Published: (2020-07-01)

How to Optimally Sequence Available Therapy Lines in Advanced Prostate Cancer
by: Katarina Antunac
Published: (2022-01-01)

External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004
by: R Miralbell, et al.
Published: (2009-09-01)

Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy
by: Jennifer L. Kalina, et al.
Published: (2017-01-01)

Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study
by: Dalsan You, et al.
Published: (2015-03-01)

Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers
by: Choi E, et al.
Published: (2022-03-01)

How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?
by: Turco F, et al.
Published: (2023-01-01)

Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies
by: Massimiliano Creta, et al.
Published: (2021-02-01)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
by: Jui-Ming Liu, et al.
Published: (2021-07-01)